CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. - Wikidata - awgldk - TriplyDB

CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.

CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.

http://www.wikidata.org/entity/Q33368192

about

The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation Open access integrated therapeutic and diagnostic platforms for personalized cardiovascular medicine Use of genetic data to guide therapy in arterial disease.Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin.Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17 Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics.The impact of smoking on post-clopidogrel platelet reactivity in patients with acute myocardial infarction.Genotyping of six clopidogrel-metabolizing enzyme polymorphisms has a minor role in the assessment of platelet reactivity in patients with acute coronary syndrome Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention.Implementing genotype-guided antithrombotic therapy.Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice.CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population.The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy.Clinically relevant genetic variations in drug metabolizing enzymes.Cardiovascular pharmacogenomics Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.Implementation of Cell Samples as Controls in National Proficiency Testing for Clopidogrel Therapy-Related CYP2C19 Genotyping in China: A Novel Approach.Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response.PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19.Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis Impact of CYP2C19 Variants on Clinical Efficacy of Clopidogrel and 1-Year Clinical Outcomes in Coronary Heart Patients Undergoing Percutaneous Coronary Intervention.Genotype and allele frequency of CYP2C19*17 in a healthy Iranian population Clopidogrel resistance is associated with long-term thrombotic events in patients implanted with drug-eluting stents.Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors Genotype-phenotype analysis of CYP2C19 in healthy saudi individuals and its potential clinical implication in drug therapy.Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Wo Recent developments in clopidogrel pharmacology and their relation to clinical outcomes.Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.The missing linkage: what pharmacogenetic associations are left to find in CYP3A?Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.Genetic causes of clopidogrel nonresponsiveness: which ones really count?Factors associated with clopidogrel nonresponsiveness.Acute coronary syndromes: from the emergency department to the catheterization laboratory-integrating evidence from recent ACS/NSTEMI trials into clinical practice: an evidence-based review of recent clinical trial results and report on a roundtable A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.Recent advances in the pharmacogenetics of clopidogrel.Genetic and non-genetic factors affecting the response to clopidogrel therapy.Personalizing antiplatelet therapy with clopidogrel.

P2860

Q26996594-0FB9DFA3-C660-4F39-8A72-3C689A0B5EDD Q27011524-2D6B3217-DCE9-4FA3-BF5A-06F49A8F085D Q30487537-30CE5840-9F0F-4F39-B05F-562E998B40E1 Q30978916-4DE5B513-09AB-4157-8B98-A47B0398B092 Q33637840-B41001B5-C8A6-4206-977B-A537F81AC3AA Q33692784-E406194D-9164-4BD7-A558-9AB5E8AC8B77 Q33704998-068D2A7C-AB43-4A62-880A-BEEDAFB31455 Q33751281-EE1F3423-E3AE-467D-A26C-F9D28FA9EEB1 Q33792075-BFBB10F4-C46A-4A3F-B187-EFCFB2A818EE Q33933475-51C8C9E6-D970-41E9-90F0-F7D2BC081B51 Q33990428-4415A9F2-C204-4A6F-856B-F6A931CC8BB3 Q34131354-74B006DC-C78C-42FC-B135-87D8A70D83CC Q34552473-97321779-77AC-485B-9262-241835C91B0D Q34703779-D00E65CA-5342-42BF-8D69-1ACBC960F47C Q35032378-8F03E1A3-13C1-4036-A7BA-9C44FC692E3A Q35447163-EF56F9B2-2205-44B8-99E9-A7F9D3B05AEE Q35603072-C8CA67F0-D900-4F72-A1B6-A76BDE587997 Q35719554-A0B28F84-83ED-4283-8C43-E00822CBF576 Q35832159-C6840AB1-4CC9-4CFB-B627-99FDBD44B2E2 Q35952367-DC3A1811-6C0E-49E2-9705-2E69EDC282C0 Q36062323-6514D852-FE14-488D-81A6-5A2FB0DF47F9 Q36216896-C102492B-3F60-4572-9548-236FE5A5C338 Q36469405-440FB9F2-8DD6-4756-921B-978E79178DB8 Q36649824-0A8F222A-C2F8-4747-9A38-3FA04253675E Q37107608-CCCBEB05-8D4C-4F47-AA7C-B61FAD9C6534 Q37140633-9996D3F3-8E41-48D3-9F3A-945F6B6D9827 Q37176949-723B112E-AC22-4A19-B839-8AF7687C4412 Q37378896-A1CC7A6B-DCA9-4622-93CF-C96A59ACEED6 Q37540088-C33FD903-C1C7-4273-8491-99F7F46B2097 Q37627874-438DB001-4E19-4481-A44C-2C854F6DFD2F Q37646778-4EF25284-4F86-4372-9292-964B244081C3 Q37693951-B15941B3-9031-432A-888A-5D46D065710A Q37697779-B07BA7CE-FB54-42E8-BE00-F0B7AFD65D58 Q37709405-A0FE0573-13D1-4723-8BDC-46125CE8F8B7 Q37813151-6DEC7276-BD3A-4DEC-B851-2C526DE1A6BC Q37908891-A40A72BB-CD5B-4D84-8678-E80C69992EE9 Q37923969-A004EF22-4920-4B75-8B7A-F148C34F7AD3 Q37972231-EA9E49B0-240E-43D8-BBFD-288FD1008C43 Q37991382-C3B4AD0A-3FF3-4A15-ADF3-D890EBEC3412 Q38040698-7DA73631-1FEB-4AE5-BDDC-032C70FB1732

P2860

CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.

http://www.wikidata.org/entity/Q33368192

description

2008 nî lūn-bûn

@nan

2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

CYP2C19 and nongenetic factors ...... r coronary stent implantation.

@ast

CYP2C19 and nongenetic factors ...... r coronary stent implantation.

@en

type

label

CYP2C19 and nongenetic factors ...... r coronary stent implantation.

@ast

CYP2C19 and nongenetic factors ...... r coronary stent implantation.

@en

prefLabel

CYP2C19 and nongenetic factors ...... r coronary stent implantation.

@ast

CYP2C19 and nongenetic factors ...... r coronary stent implantation.

@en

P1433

Q33368192-8DE36F7D-FC17-486C-9DB0-A13E24F989F7

P1476

Q33368192-22B5AA95-6F9D-4FE8-A417-4A60C9E38834

P2093

Q33368192-006F3365-6050-4BE4-8E21-E46A9BBF1574

Q33368192-136FFCCA-D782-4120-9A46-9A2C3F08621D

Q33368192-139908E6-52AB-4920-BD7E-928B00A36E9C

Q33368192-3BA3124B-1653-4BA1-8621-7BE180458687

Q33368192-6EC33316-3C9E-4E63-BF70-1E4237B25693

Q33368192-8312725E-C32B-4C68-ADD6-3495BFA86B86

Q33368192-8DAF3DA8-72A0-4200-B286-DF153E30F30A

Q33368192-91332848-9F0D-4340-902B-A17598BDC4B6

Q33368192-950BCA3E-6E90-4E29-AFBB-EEB4D30D7259

P2860

Q33368192-07A308D8-85DA-42E7-9215-BD21E5A5B6B3

Q33368192-0C6C14A8-9884-4A3C-B385-6FF1EB62363E

Q33368192-1F13D924-F4D1-41B0-8531-07F200B033CD

Q33368192-1F9F1A11-BBE3-47D6-8B41-FDA3DA2920DB

Q33368192-23DDC4D5-D1C5-4704-9536-5E66AEC38061

Q33368192-243E42CB-D2FF-412A-BE35-1D8B581CC65E

Q33368192-2ADA8111-B456-429E-AA1E-4C02DBD40C35

Q33368192-2E1E7FC6-5D2D-4B8D-B4DB-E452264827B4

Q33368192-36935B1B-D99D-4117-9247-083AF4604B13

Q33368192-3C84CF90-E009-462E-808C-61BDDD14DCF7

P304

Q33368192-A835205A-935A-499D-A584-5B71E2261584

P31

Q33368192-6F9A4E9E-11DA-40E9-9ED7-56FF8BDF832E

P356

Q33368192-67C177F2-C474-4EC0-AE64-6E227F47A59A

P433

Q33368192-D22FB4E8-3B6A-4FA3-A246-5E496384C92E

P478

Q33368192-E4640D63-C530-41AB-9364-FF1A6D2AB0EC

P50

Q33368192-F955385A-5758-4762-A93F-62CC50D68E7F

P577

Q33368192-5B940214-1AA9-458C-900E-DBB66CE385B0

P698

Q33368192-2D832E3A-0728-4A9F-9154-A6C986E3AB5C

P921

Q33368192-9070B5DA-29A2-4DD8-B065-77453CDAE38B

P356

14622416.9.9.1251

P1433

Pharmacogenomics

P1476

CYP2C19 and nongenetic factors ...... r coronary stent implantation.

@en

P2093

Christian Bischofs

http://www.w3.org/2001/XMLSchema#string

Christine Zuern

http://www.w3.org/2001/XMLSchema#string

Juergen Dippon

http://www.w3.org/2001/XMLSchema#string

Klaus Moerike

http://www.w3.org/2001/XMLSchema#string

Matthias Schwab

http://www.w3.org/2001/XMLSchema#string

Meinrad Gawaz

http://www.w3.org/2001/XMLSchema#string

Stefan Winter

http://www.w3.org/2001/XMLSchema#string

Tobias Geisler

http://www.w3.org/2001/XMLSchema#string

Verena Buse

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of the platelet ADP receptor targeted by antithrombotic drugs

Platelet activation after stenting with heparin-coated versus noncoated stents

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel

Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

P304

1251-1259

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/14622416.9.9.1251

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Elke Schaeffeler

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18781853

http://www.w3.org/2001/XMLSchema#string

P921